Abstract
VHL as a tumor suppressor gene is the most common mutant gene in clear cell renal cell carcinoma (ccRCC), and inactivating alterations of VHL gene lead to HIF-2α accumulation, which induces the tumor progression. Recently the inhibitor of HIF-2α, Belzutifan was approved by FDA for patients with solid tumors harboring germline VHL mutations. However, the prevalence of somatic VHL variants in Chinese solid tumors remained unclear.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
